In a study, hemodialysis patients who used phosphate binders had up to a 44% decreased risk of dying from infection than those who did not use the drugs. Phosphate binder use by patients on ...
In its first label update since sodium zirconium cyclosilicate was approved in 2018, FDA has a dosage regimen specifically to treat hyperkalemia in stable hemodialysis patients. The FDA has approved a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback